Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9460010 | 1.00 | TBXA2R (0.41) | TBXA2RKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL27455193 | 0.84 | ALDH1A1 (0.41) | KMT2AKDM4EALDH1A1MAPTPKM | |
| SCHEMBL28789383 | 0.84 | TBXA2R (0.44) | TBXA2RKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL27553812 | 0.82 | CYP26A1 (0.50) | TBXA2RKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL27819912 | 0.82 | PIK3R1 (0.45) | TBXA2RHTTCYP26A1SMN1; SMN2CYP19A1 | |
| SCHEMBL27565163 | 0.82 | PIK3R1 (0.45) | TBXA2RHTTCYP26A1SMN1; SMN2CYP19A1 | |
| SCHEMBL26660824 | 0.81 | CYP26A1 (0.41) | KMT2AKDM4EALDH1A1MAPTPKM | |
| SCHEMBL25196732 | 0.80 | CYP26A1 (0.40) | TBXA2RKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL4552326 | 0.79 | KMT2A (0.39) | TBXA2RKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL29852421 | 0.79 | KMT2A (0.50) | KMT2AKDM4EALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101531636-B | Method for synthesizing 2-(1-imidazol)ethylamine | UNIV HEFEI TECHNOLOGY | 2010-12-08 | — | — | CN | claimed |
| CN-101531636-A | Method for synthesizing 2-(1-imidazol)ethylamine | UNIV HEFEI TECHNOLOGY | 2009-09-16 | — | — | CN | claimed |
| CN-101531636-B | Method for synthesizing 2-(1-imidazol)ethylamine | UNIV HEFEI TECHNOLOGY | 2010-12-08 | — | — | CN | disclosed |
| CN-101531636-B | Method for synthesizing 2-(1-imidazol)ethylamine | UNIV HEFEI TECHNOLOGY | 2010-12-08 | — | — | CN | disclosed |
| CN-101531636-A | Method for synthesizing 2-(1-imidazol)ethylamine | UNIV HEFEI TECHNOLOGY | 2009-09-16 | — | — | CN | disclosed |
| CN-101531636-A | Method for synthesizing 2-(1-imidazol)ethylamine | UNIV HEFEI TECHNOLOGY | 2009-09-16 | — | — | CN | disclosed |
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6528535-B2 | Anticancer agents; restenosis | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| CN-1086701-C | Chloropyridylcarbonylazoles and fungicides for agriculture and horticulture | BAYER AGROCHEM KK (JP) | 2002-06-26 | — | — | CN | disclosed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | disclosed |
| EP-0763530-B1 | Chloropyridylcarbonyl derivatives and their use as microbiocides | BAYER AGROCHEM KK (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6133303-A | VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0966446-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5973156-A | Piperidine and tetrahydropyridine derivatives | MERCK SHARP & DOME LTD. (GB) | 1999-10-26 | — | — | US | disclosed |
| US-5849767-A | Chloropyridylcarbonyl derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 1998-12-15 | — | — | US | disclosed |
| WO-1998034921-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1998-08-13 | — | — | WO | disclosed |
| CN-1147505-A | Chloropyridylcarbonylazoles and fungicides for agriculture and horticulture | BAYER AGROCHEM KK (JP) | 1997-04-16 | — | — | CN | disclosed |
| EP-0763530-A1 | Chloropyridylcarbonyl derivatives and their use as microbiocides | NIHON BAYER AGROCHEM K.K. (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | FNTA, FNTB, SREBF1 | TBXA2R 1720/4885KMT2A 3893/4885KDM4E 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.